Medicago

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Medicago sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 8 completed early-phase tilt top decile by trial count

Medicago: 9 sponsored US clinical trials, none currently recruiting.

Medicago sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is RNA Virus Infections, with 1 trials.

Top-decile sponsor footprint

Medicago ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

NCT04636697
COMPLETED Phase 1

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

NCT04622592
COMPLETED Phase 3

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

NCT03739112
COMPLETED Phase 3

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

NCT03301051
COMPLETED Phase 2

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

NCT02831751
COMPLETED Phase 2

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

NCT02768805
COMPLETED Phase 2

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

NCT02233816
COMPLETED Phase 1

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

NCT01991587
COMPLETED Phase 1

Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults

NCT01302990

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4
Phase 3 2

Therapeutic Areas

RNA Virus Infections 1
Virus Diseases 1
Respiratory Tract Infections 1
Respiratory Tract Diseases 1
Influenza 1
SARS CoV 2 Infection 1

How the Medicago early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 8 completed (89%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: RNA Virus Infections (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Medicago: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Medicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Medicago4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Medicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Medicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Medicago page

9 registered trials is a research-attention snapshot, not an endorsement of Medicago or any single study.

  • None of Medicago's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • RNA Virus Infections is the condition Medicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See RNA Virus Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Medicago pipeline card: 9 registered trials from official public datasets.Report a data error.